
Title:
Minoxidil
Text:
Medication used to treat hair loss


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}MinoxidilClinical dataTrade namesRegaine, Loniten, Keeps, othersAHFS/Drugs.comMonographMedlinePlusa682608License data
US DailyMed: Minoxidil
Pregnancycategory
AU: C[1]

Routes ofadministrationBy mouth, topicalATC codeC02DC01 (WHO) D11AX01 (WHO)Legal statusLegal status
AU: S4 (Prescription only) / S2[1][2][3]
UK: General sales list (GSL, OTC) / POM[4][5][6]
US: OTC / Rx-only[7][8]
Pharmacokinetic dataMetabolismPrimarily liverElimination half-life4.2 hExcretionKidneyIdentifiers
IUPAC name
3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
CAS Number38304-91-5 YPubChem CID4201IUPHAR/BPS4254DrugBankDB00350 NChemSpider10438564 YUNII5965120SH1KEGGD00418 NChEBICHEBI:6942 NChEMBLChEMBL802 NPDB ligandMXD (PDBe, RCSB PDB)CompTox Dashboard (EPA)DTXSID9040685 ECHA InfoCard100.048.959 Chemical and physical dataFormulaC9H15N5OMolar mass209.253 g·mol−13D model (JSmol)Interactive imageMelting point248 °C (478 °F)Solubility in water<1
SMILES
Nc1cc(nc(N)[n+]1[O-])N2CCCCC2

InChI
InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6H,1-5,10H2,(H2,11,12) NKey:ZFMITUMMTDLWHR-UHFFFAOYSA-N N
.mw-parser-output .nobold{font-weight:normal} NY (what is this?)  (verify)
Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide), sold under the brand name Rogaine among others, is a medication used for the treatment of high blood pressure and pattern hair loss.[4][5][6] It is an antihypertensive vasodilator.[9] It is available as a generic medication by prescription in oral tablet form and over the counter as a topical liquid or foam.[7][8][10][11] Minoxidil, when used for hypertension, is generally reserved for use in severe hypertension patients who can't respond to at least two agents and a diuretic. Minoxidil is also generally administered with a loop diuretic to prevent the sodium and potassium retention. It may also cause a reflex tachycardia and thus is prescribed with a beta-blocker.

Contents

1 Medical uses
2 Mechanism of action
3 History

3.1 Initial application
3.2 Hair growth


4 Side effects
5 Trade names
6 See also
7 References
8 External links



Medical uses[edit]
Minoxidil, applied topically, is widely used for the treatment of hair loss. It is effective in helping promote hair growth in people with androgenic alopecia regardless of sex.[12] Minoxidil must be used indefinitely for continued support of existing hair follicles and the maintenance of any experienced hair regrowth.[5][6]
Its effect in people with alopecia areata is unclear.[13]

Mechanism of action[edit]
The mechanism by which minoxidil promotes hair growth is not fully understood. Minoxidil is an adenosine 5'-triphosphate-sensitive  potassium channel opener,[14] causing hyperpolarization of cell membranes. Theoretically, by widening blood vessels and opening potassium channels, it allows more oxygen, blood, and nutrients to the follicles. Moreover, minoxidil contains a nitric oxide moiety and may act as a nitric oxide agonist. This may cause follicles in the telogen phase to shed, which are then replaced by thicker hairs in a new anagen phase. Minoxidil is a prodrug that is converted by sulfation via the sulfotransferase enzyme SULT1A1 to its active form, minoxidil sulfate. The effect of minoxidil is mediated by adenosine, which triggers intracellular signal transduction via both adenosine A1 receptors and two sub-types of adenosine A2 receptors (A2A and A2B receptors).[15] Minoxidil acts as an activator of the Kir6/SUR2 channel upon selective binding to SUR2.[16] The expression of SUR2B in dermal papilla cells might play a role in the production of adenosine.[15] Minoxidil induces cell growth factors such as VEGF, HGF, IGF-1 and potentiates HGF and IGF-1 actions by the activation of uncoupled sulfonylurea receptor on the plasma membrane of dermal papilla cells.[17]
A number of in vitro effects of minoxidil have been described in monocultures of various skin and hair follicle cell types including stimulation of cell proliferation, inhibition of collagen synthesis, and stimulation of vascular endothelial growth factor, prostaglandin synthesis and leukotriene B4 expression.[18]
Minoxidil causes a redistribution of cellular iron through its apparent capacity to bind this metal ion. By binding iron in a Fenton-reactive form, intracellular hydroxyl radical production would ensue, but hydroxyl would be immediately trapped and scavenged by the minoxidil to generate a nitroxyl radical. It is presumed that this nitroxyl radical will be capable of reduction by glutathione to reform minoxidil. Such a process would cycle until the minoxidil is otherwise metabolized and would result in rapid glutathione depletion with glutathione disulphide formation and therefore with concomitant consumption of NADPH/ NADH and other reducing equivalents.[19] Minoxidil inhibited PHD by interfering with the normal function of ascorbate, a cofactor of the enzyme, leading to a stabilization of HIF-1α protein and a subsequent activation of HIF-1. In an in vivo angiogenesis assay, millimolar minoxidil increased blood vessel formation in a VEGF-dependent manner. Minoxidil inhibition of PHD occurs via interrupting ascorbate binding to iron.[20] The structural feature of positioning amines adjacent to nitric oxide may confer the ability of millimolar minoxidil to chelate iron, thereby inhibiting PHD. Minoxidil is capable of tetrahydrobiopterin inhibition as a cofactor for nitric oxide synthase.[21]
Minoxidil stimulates prostaglandin E2 production by activating COX-1[22] and prostaglandin endoperoxide synthase-1 but inhibits prostacyclin production. Additionally, expression of the prostaglandin E2 receptor, the most upregulated target gene in the β-catenin pathway of DP cells, was enhanced by minoxidil, which may enable hair follicles to grow continuously and maintain the anagen phase.[23]
Due to anti-fibrotic activity of minoxidil inhibition of enzyme lysyl hydroxylase present in fibroblast may result in synthesis of a hydroxylysine-deficient collagen. Minoxidil can also potentially stimulate elastogenesis in aortic smooth muscle cells, and in skin fibroblasts in a dose-dependent manner. In hypertensive rats, minoxidil increases elastin level in the mesenteric, abdominal, and renal arteries by a decrease in "elastase" enzyme activity in these tissues. In rats, potassium channel openers decrease calcium influx which inhibits elastin gene transcription through extracellular signal-regulated kinase ½ (ERK 1/2)-activator protein 1 signaling pathway. ERK 1/2 increases, through elastin gene transcription, adequately cross-linked elastic fiber content synthetized by smooth muscle cells, and decreases the number of cells in the aorta.[24]
Minoxidil possesses alpha 2-adrenoceptor agonist activity,[25] stimulates the peripheral sympathetic nervous system (SNS) by way of carotid and aortic baroreceptor reflexes. Minoxidil administration also brings an increase in plasma renin activity, largely due to the aforementioned activation of the SNS. This activation of the renin-angiotensin axis further prompts increased biosynthesis of aldosterone; whereas plasma and urinary aldosterone levels are increased early in the course of treatment with minoxidil, over time these values tend to normalize presumably because of accelerated metabolic clearance of aldosterone in association with hepatic vasodilation.[26]
Minoxidil may be involved in the inhibition of serotonergic (5-HT2) receptors.[27]
Minoxidil might increase blood-tumor barrier permeability in a time-dependent manner by down-regulating tight junction protein expression and this effect could be related to ROS/RhoA/PI3K/PKB signal pathway.[28] Minoxidil significantly increases ROS concentration when compared to untreated cells.
In vitro Minoxidil treatment resulted in a 0.22 fold change for 5α-R2 (p < 0.0001). This antiandrogenic effect of minoxidil, shown by significant downregulation of 5α-R2 gene expression in HaCaT cells, may be one of its mechanisms of action in alopecia.[29]
Minoxidil is less effective when the area of hair loss is large. In addition, its effectiveness has largely been demonstrated in younger men who have experienced hair loss for less than 5 years. Minoxidil use is indicated for central (vertex) hair loss only.[30] Two clinical studies are being conducted in the US for a medical device that may allow patients to determine if they are likely to benefit from minoxidil therapy.[31]

History[edit]
Initial application[edit]
Minoxidil was developed in the late 1950s by the Upjohn Company (later became part of Pfizer) to treat ulcers. In trials using dogs, the compound did not cure ulcers, but proved to be a powerful vasodilator. Upjohn synthesized over 200 variations of the compound, including the one it developed in 1963 and named minoxidil.[32] These studies resulted in the U.S. Food and Drug Administration (FDA) approving minoxidil (with the brand name 'Loniten') in the form of oral tablets to treat high blood pressure in 1979.[33][34]

Hair growth[edit]
When Upjohn received permission from the U.S. Food and Drug Administration (FDA) to test the new drug as medicine for hypertension they approached Charles A. Chidsey MD, Associate Professor of Medicine at the University of Colorado School of Medicine.[32] He conducted two studies,[35][36] the second study showing unexpected hair growth. Puzzled by this side-effect, Chidsey consulted Guinter Kahn (who while a dermatology resident at the University of Miami had been the first to observe and report hair development on patients using the minoxidil patch) and discussed the possibility of using minoxidil  for treating hair loss.
Kahn along with his colleague Paul J. Grant MD had obtained a certain amount of the drug and conducted their own research, since they were first to make the side effect observation.  Neither Upjohn or Chidsey at the time were aware of the side effect of hair growth.[37] The two doctors had been experimenting with a 1% solution of minoxidil mixed with several alcohol-based liquids.[38]   Both parties filed patents to use the drug for hair loss prevention, which resulted in a decade-long trial between Kahn and Upjohn, which ended with Kahn's name included in a consolidated patent (U.S. #4,596,812 Charles A Chidsey, III and Guinter Kahn) in 1986 and royalties from the company to both Kahn and Grant.[37]
Meanwhile, the effect of minoxidil on hair loss prevention was so clear that in the 1980s physicians were prescribing Loniten off-label to their balding patients.[34]
In August 1988, the FDA approved the drug for treating baldness in men[34][38] under the brand name "Rogaine" (FDA rejected Upjohn's first choice, Regain, as misleading[39]). The agency concluded that although "the product will not work for everyone", 39% of the men studied had "moderate to dense hair growth on the crown of the head".[39]
In 1991, Upjohn made the product available for women.[38]
On February 12, 1996, the FDA approved both the over-the-counter sale of the medication and the production of generic formulations of minoxidil.[34] Upjohn replied to that by lowering prices to half the price of the prescription drug[38] and by releasing a prescription 5% formula of Rogaine in 1997.[34][40] In 1998, a 5% formulation of minoxidil was approved for nonprescription sale by the FDA.[41] The 5% aerosol foam formula was approved for medical use in the US in 2006.[42][43] The generic versions of the 5% aerosol foam formula were approved in 2017.[44][45]
In 2017, JAMA published a study of pharmacy prices in four states for 41 over-the-counter minoxidil products which were "gender-specified." The authors found that the mean price for minoxidil solutions was the same for women and men even though the women's formulations were 2% and the men's were 5%, while the mean price for minoxidil foams, which were all 5%, was 40% higher for women. The authors noted this was the first time gender-based pricing had been shown for a medication.[46]

  [47]
Side effects[edit]
Topically applied minoxidil is generally well tolerated, but common side effects include itching of the eye, itching, redness or irritation at the treated area, and unwanted hair growth elsewhere on the body. Exacerbation of hair loss/alopecia has been reported.[48] Other side effects may include rash, itching, difficulty breathing, swelling of the mouth, face, lips, or tongue, chest pain, dizziness, fainting, tachycardia, headache, sudden and unexplained weight gain, or swelling of the hands and feet.[48] Rare side effects are erectile dysfunction, depression, anxiety, decreased libido, skin disorders.[47] Temporary hair loss is a common side effect of minoxidil treatment, a process referred to as "shedding."[49]
Alcohol and propylene glycol present in some topical preparations may dry the scalp, resulting in dandruff and contact dermatitis.[50] Cases of allergic reactions to minoxidil or the non-active ingredient propylene glycol, which is found in some topical minoxidil formulations, have been reported.
Side effects of oral minoxidil may include swelling of the face and extremities, rapid heartbeat, or lightheadedness. Cardiac lesions, such as focal necrosis of the papillary muscle and subendocardial areas of the left ventricle, have been observed in laboratory animals treated with minoxidil.[51] Pseudoacromegaly is an extremely rare side effect reported with large doses of oral minoxidil.[52]
In 2013 or 2014 a seven-year-old girl was admitted to a children's hospital in Toulouse in France after accidentally ingesting a teaspoon of Alopexy (a brand name for minoxidil in France). The child vomited constantly after ingestion and showed hypotension and tachycardia for 40 hours.[53]  The authors of the report on the incident stressed that the product should be kept out of reach of children, and urged manufacturers to consider more secure child-resistant packaging.[54]
Minoxidil may cause hirsutism, although it is exceedingly rare and reversible by discontinuation of the drug.[55]
Minoxidil is suspected to be highly toxic to cats, even in small doses, as there are reported cases of cats dying shortly after coming in contact with minimal amounts of the substance.[56][57]

Trade names[edit]
As of June 2017[update], Minoxidil was marketed under many trade names worldwide: Alomax, Alopek, Alopexy, Alorexyl, Alostil, Aloxid, Aloxidil, Anagen, Apo-Gain, Axelan, Belohair, Boots Hair Loss Treatment, Botafex, Capillus, Carexidil, Coverit, Da Fei Xin, Dilaine, Dinaxcinco, Dinaxil, Ebersedin, Eminox, Folcare, Guayaten, Hair Grow, Hair-Treat, Hairgain, Hairgaine, Hairgrow, Hairway, Headway, Inoxi, Ivix, Keranique, Lacovin, Locemix, Loniten, Lonnoten, Lonolox, Lonoten, Loxon, M E Medic, Maev-Medic, Mandi, Manoxidil, Mantai, Men's Rogaine, Minodil, Minodril, Minostyl, Minovital, Minox, Minoxi, Minoxidil, Minoxidilum, Minoximen, Minoxiten, Minscalp, Mintop, Modil, Morr, Moxidil, Neo-Pruristam, Neocapil, Neoxidil, Nherea, Noxidil, Oxofenil, Pilfud, Pilogro, Pilomin, Piloxidil, Recrea, Regain, Regaine, Regaxidil, Regro, Regroe, Regrou, Regrowth, Relive, Renobell Locion, Reten, Rexidil, Rogaine, Rogan, Si Bi Shen, Splendora, Superminox, Trefostil, Tricolocion, Tricoplus, Tricovivax, Tricoxane, Trugain, Tugain, Unipexil, Vaxdil, Vius, Womens Regaine, Xenogrow, Xue Rui, Ylox, and Zeldilon.[58]  It was also marketed as combination drug with amifampridine under the brand names Gainehair and Hair 4 U, and as a combination with tretinoin and clobetasol under the brand name Sistema GB.[58]

See also[edit]
Diazoxide
Finasteride
Kopexil, an analog of minoxidil missing the piperidine substituent
Pinacidil
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Loniten Product Information". Therapeutic Goods Administration (TGA). Retrieved August 15, 2021.

^ http://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=3EE19DEB44A99CB3CA2577DD0001271C&agid=(PrintDetailsPublic)&actionid=1

^ "Search the TGA website".

^ Jump up to: a b "Loniten Tablets 5mg - Summary of Product Characteristics (SmPC)". (emc). November 24, 2020. Retrieved August 15, 2021.

^ Jump up to: a b c "Regaine for Men Extra Strength Scalp Foam 5% w/w Cutaneous Foam (GSL) - Summary of Product Characteristics (SmPC)". (emc). April 27, 2021. Retrieved August 15, 2021.

^ Jump up to: a b c "Regaine for Women Once a Day Scalp Foam 5% w/w Cutaneous Foam - Summary of Product Characteristics (SmPC)". (emc). October 28, 2020. Retrieved August 15, 2021.

^ Jump up to: a b "Minoxidil tablet". DailyMed. Retrieved August 15, 2021.

^ Jump up to: a b "Minoxidil aerosol, foam". DailyMed. Retrieved August 15, 2021.

^ "Vasodilators". mayoclinic.com. Archived from the original on March 9, 2011.

^ "Mens Rogaine Extra Strength Unscented- minoxidil solution". DailyMed. Retrieved August 15, 2021.

^ "Womens Rogaine Unscented- minoxidil solution". DailyMed. Retrieved August 15, 2021.

^ Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.

^ Hordinsky M, Donati A (July 2014). "Alopecia areata: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 231–46. doi:10.1007/s40257-014-0086-4. PMID 25000998. S2CID 32253.

^ Wang T (February 2003). "The effects of the potassium channel opener minoxidil on renal electrolytes transport in the loop of henle". The Journal of Pharmacology and Experimental Therapeutics. 304 (2): 833–40. doi:10.1124/jpet.102.043380. PMID 12538840. S2CID 6948410.

^ Jump up to: a b Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S (December 2001). "Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil". The Journal of Investigative Dermatology. 117 (6): 1594–1600. doi:10.1046/j.0022-202x.2001.01570.x. PMID 11886528. The expression of sulfonylurea receptor 2B and of the adenosine A1, A2A, and A2B receptors was detected in dermal papilla cells by means of reverse transcription polymerase chain reaction analysis.

^ Fukushiro-Lopes D, Hegel AD, Russo A, Senyuk V, Liotta M, Beeson GC,  et al. (May 8, 2020). "Repurposing Kir6/SUR2 Channel Activator Minoxidil to Arrests Growth of Gynecologic Cancers". Frontiers in Pharmacology. 11: 577. doi:10.3389/fphar.2020.00577. PMC 7227431. PMID 32457608.

^ Otomo S (March 2002). "[Hair growth effect of minoxidil]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 119 (3): 167–74. doi:10.1254/fpj.119.167. PMID 11915519.

^ Messenger AG, Rundegren J (February 2004). "Minoxidil: mechanisms of action on hair growth". The British Journal of Dermatology. 150 (2): 186–94. doi:10.1111/j.1365-2133.2004.05785.x. PMID 14996087. S2CID 19308112.{{cite journal}}:  CS1 maint: url-status (link)

^ Chung, Lip Yong; Andrews, Andrea M.; Schmidt, Richard J.; Turner, Terence D. (1992). "Effects of minoxidil on cell proliferation and intracellular glutathione status of murine (L929) fibroblasts".  In Harding, Keith G.; Leaper, D. L.; Turner, T. D. (eds.). Proceedings of the 1st European Conference on Advances in Wound Management, Cardiff, 4-6 September 1991. Macmillan Magazines. pp. 122–128. ISBN 978-0-333-58645-7.

^ Yum S, Jeong S, Kim D, Lee S, Kim W, Yoo JW,  et al. (December 2017). "Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase". International Journal of Molecular Sciences. 19 (1): 53. doi:10.3390/ijms19010053. PMC 5796003. PMID 29295567.

^ .mw-parser-output .citation{word-wrap:break-word}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}US 5874433, Gross, Steven S, "Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis", published 1999-02-23 

^ Hwang JH, Chu H, Ahn Y, Kim J, Kim DY (April 2019). "HMGB1 promotes hair growth via the modulation of prostaglandin metabolism". Scientific Reports. 9 (1): 6660. Bibcode:2019NatSR...9.6660H. doi:10.1038/s41598-019-43242-2. PMC 6491442. PMID 31040377.

^ Suchonwanit P, Thammarucha S, Leerunyakul K (2019). "Minoxidil and its use in hair disorders: a review". Drug Design, Development and Therapy. 13: 2777–2786. doi:10.2147/DDDT.S214907. PMC 6691938. PMID 31496654.

^ Kassai B, Bouyé P, Gilbert-Dussardier B, Godart F, Thambo JB, Rossi M,  et al. (May 2019). "Minoxidil versus placebo in the treatment of arterial wall hypertrophy in children with Williams Beuren Syndrome: a randomized controlled trial". BMC Pediatrics. 19 (1): 170. doi:10.1186/s12887-019-1544-1. PMC 6537216. PMID 31138170.

^ Sharma N, Mehta AA, Santani DD, Goyal RK (September 1997). "Evidence for alpha 2-adrenoceptor agonist activity of minoxidil". The Journal of Pharmacy and Pharmacology. 49 (9): 935–7. doi:10.1111/j.2042-7158.1997.tb06139.x. PMID 9306265. S2CID 84233773.{{cite journal}}:  CS1 maint: url-status (link)

^ Sica, Domenic A. (May 2004). "Minoxidil: An Underused Vasodilator for Resistant or Severe Hypertension". The Journal of Clinical Hypertension. 6 (5): 283–287. doi:10.1111/j.1524-6175.2004.03585.x. PMID 15133413. S2CID 21366804.

^ Wasiński R, Godlewski G, Wróbel B, Buckzko W (May 1995). "Interactions of minoxidil with vasoconstrictive agents in isolated rat tail artery". Acta Poloniae Pharmaceutica. 52 (3): 253–6. PMID 8960256.

^ Gu YT, Xue YX, Wang YF, Wang JH, Chen X, ShangGuan QR,  et al. (December 2013). "Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway". Neuropharmacology. 75: 407–15. doi:10.1016/j.neuropharm.2013.08.004. PMID 23973310. S2CID 20676988.

^ Pekmezci E, Türkoğlu M (December 2017). "Minoxidil Acts as an Antiandrogen: A Study of 5α-reductase Type 2 Gene Expression in a Human Keratinocyte Cell Line" (PDF). Acta Dermatovenerologica Croatica. 25 (4): 271–275. PMID 30064598.

^ Scow DT, Nolte RS, Shaughnessy AF (April 1999). "Medical treatments for balding in men". American Family Physician. 59 (8): 2189–94, 2196. PMID 10221304. Archived from the original on September 28, 2012.

^ Clinical trial number NCT02198261 for "Minoxidil Response Testing in Males With Androgenetic Alopecia" at ClinicalTrials.gov

^ Jump up to: a b Martin D (September 19, 2014). "Guinter Kahn, Inventor of Baldness Remedy, Dies at 80". The New York Times. Archived from the original on November 5, 2014. Retrieved May 11, 2015.

^ "Loniten: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved August 15, 2021.

^ Jump up to: a b c d e Conrad P (2008). "Extension". The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders. JHU Press. p. 37. ISBN 978-0801892349. Retrieved May 11, 2015. (Google Books)

^ Gilmore E, Weil J, Chidsey C (March 1970). "Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade". The New England Journal of Medicine. 282 (10): 521–7. doi:10.1056/NEJM197003052821001. PMID 4391708.

^ Gottlieb TB, Katz FH, Chidsey CA (March 1972). "Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine". Circulation. 45 (3): 571–82. doi:10.1161/01.CIR.45.3.571. PMID 4401051.

^ Jump up to: a b Goldfarb NM (March 2006). "When Patents Became Interesting in Clinical Research" (PDF). The Journal of Clinical Research Best Practices. 2 (3). Archived from the original (PDF) on May 18, 2015. Retrieved May 11, 2015.

^ Jump up to: a b c d Lester W (May 13, 1996). "Hair-rasing tale: no fame for men who discovered Rogaine". The Daily Gazette. Retrieved May 11, 2015.

^ Jump up to: a b Kuntzman G (2001). Hair!: Mankind's Historic Quest to End Baldness. Random House Publishing Group. p. 172. ISBN 978-0679647096. Retrieved May 11, 2015. (Google Books)

^ "Drug Approval Package: Rogaine NDA# 020834". U.S. Food and Drug Administration (FDA). August 8, 2003. Retrieved August 15, 2021.

^ Pray SW (2006). Nonprescription Product Therapeutics. Lippincott Williams & Wilkins. p. 663. ISBN 978-0781734981. Retrieved May 11, 2015. (Google Books)

^ "Drug Approval Package: Men's Rogaine (5% Minoxidil) NDA #021812". U.S. Food and Drug Administration (FDA). May 6, 2008. Retrieved August 15, 2021.

^ "Rogaine: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved August 15, 2021.

^ "Minoxidil: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved August 15, 2021.

^ "CDER 2017 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). February 20, 2018. Retrieved August 15, 2021.

^ Wehner MR, Nead KT, Lipoff JB (August 2017). "Association Between Gender and Drug Cost for Over-the-Counter Minoxidil". JAMA Dermatology. 153 (8): 825–826. doi:10.1001/jamadermatol.2017.1394. PMC 5817599. PMID 28593214.

^ Jump up to: a b Wu M, Yu Q, Li Q (December 2016). "Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases". Oncotarget. 7 (50): 82074–82084. doi:10.18632/oncotarget.12617. PMC 5347675. PMID 27738338.

^ Jump up to: a b "Rogaine Side Effects in Detail". Drugs.com. Retrieved December 8, 2020.

^ "FAQs for Men - Hair Growth Education". ROGAINE. Archived from the original on November 10, 2009. Retrieved November 20, 2009.

^ Pray, W. Steven (2001). "Dandruff and Seborrheic Dermatitis". US Pharmacist. 26 (4): 16–24. Archived from the original on October 28, 2010.

^ "Minoxidil Official FDA information, side effects and uses". Drugs.com. Archived from the original on September 22, 2017.

^ Nguyen KH, Marks JG (June 2003). "Pseudoacromegaly induced by the long-term use of minoxidil". Journal of the American Academy of Dermatology. 48 (6): 962–5. doi:10.1067/mjd.2003.325. PMID 12789195.

^ Nguyen KH, Marks JG (June 2003). "Pseudoacromegaly induced by the long-term use of minoxidil". Journal of the American Academy of Dermatology. 48 (6): 962–5. doi:10.1097/PEC.0000000000000301. PMID 12789195. S2CID 205932483.

^ Neumann J (December 10, 2014). "Hair loss treatment may be dangerous to kids". Reuters.

^ Dawber RP, Rundegren J (May 2003). "Hypertrichosis in females applying minoxidil topical solution and in normal controls". Journal of the European Academy of Dermatology and Venereology. 17 (3): 271–5. doi:10.1046/j.1468-3083.2003.00621.x. PMID 12702063. S2CID 23329383.

^ "Minoxidil Warning". www.showcatsonline.com. Archived from the original on March 8, 2019.

^ DeClementi C, Bailey KL, Goldstein SC, Orser MS (November 2004). "Suspected toxicosis after topical administration of minoxidil in 2 cats". Journal of Veterinary Emergency and Critical Care. 14 (4): 287–292. doi:10.1111/j.1476-4431.2004.04014.x.

^ Jump up to: a b Drugs.com International brand names for minoxidil Archived August 8, 2017, at the Wayback Machine Page accessed June 26, 2017


External links[edit]
"Minoxidil". Drug Information Portal. U.S. National Library of Medicine.
"Minoxidil Topical". MedlinePlus.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteNonsympatholytic vasodilatory antihypertensives (C02)Nitrovasodilator (arterioles and venules)
Nitroprusside #
Hydrazinophthalazines (arterioles)
Hydralazine #
Dihydralazine
Endralazine
Cadralazine
Pildralazine
Potassium channel openers (arterioles)
Minoxidil
Diazoxide
Calcium channel blockers (arterioles)
see list

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteOther dermatological preparations (D11)Anti-seborrheics
Antiandrogens
Bicalutamide
Cyproterone acetate
Flutamide
Spironolactone
Antifungals
Bifonazole
Cetrimonium bromide (cetrimide)
Ciclopirox olamine (ciclopirox)
Climbazole
Clotrimazole
Ketoconazole
Miconazole
Piroctone olamine
Selenium disulfide (selenium sulfide)
Xenysalate
Zinc pyrithione (pyrithione zinc)
Antihistamines
Calcineurin inhibitors
Cyclosporin
Pimecrolimus
Tacrolimus
Isotretinoin
Keratolytics
Coal tar
Resorcinol
Salicylic acid
Sulfur
Urea (urea-containing cream)
Lithium salts
Lithium gluconate
Lithium succinate
Topical corticosteroids (e.g., hydrocortisone)
Skin lightening
Hydroquinone
Mequinol
Monobenzone
Skin darkening
Afamelanotide
Melanotan II
Anti-inflammatories
Oxaceprol
Gamolenic acid
Pimecrolimus
Tacrolimus
Alitretinoin
Topical corticosteroids (e.g., hydrocortisone)
Alopecia treatments
5α-Reductase inhibitors
Alfatradiol
Dutasteride
Finasteride
Saw palmetto extract
Antiandrogens
Bicalutamide
Cyproterone acetate
Flutamide
Spironolactone
Topilutamide (fluridil)
Potassium channel openers
Minoxidil
Others
Nepidermin
Hair growth inhibitors
5α-Reductase inhibitors
Dutasteride
Finasteride
Antiandrogens
Bicalutamide
Cyproterone acetate
Flutamide
Spironolactone
Eflornithine
Others
Androgens (e.g., testosterone)
Brimonidine
Calcium gluconate
Estrogens (e.g., estradiol)
Hyaluronic acid
Magnesium sulfate
Pregnenolone acetate
Progestogens (e.g., progesterone)
Povidone-iodine
Tiratricol

vteIon channel modulatorsCalciumVDCCsBlockers
L-type-selective: Dihydropyridines: Amlodipine
Aranidipine
Azelnidipine
Barnidipine
Clevidipine
Cronidipine
Darodipine
Dexniguldipine
Elgodipine
Elnadipine
Felodipine
Flordipine
Furnidipine
Iganidipine
Isradipine
Lacidipine
Lemildipine
Lercanidipine
Levamlodipine
Levniguldipine
Manidipine
Mepirodipine
Mesudipine
Nicardipine
Nifedipine
Niguldipine
Niludipine
Nilvadipine
Nimodipine
Nisoldipine
Nitrendipine
Olradipine
Oxodipine
Palonidipine
Pranidipine
Ryodipine (riodipine)
Sagandipine
Sornidipine
Teludipine
Tiamdipine
Trombodipine
Vatanidipine; Diltiazem derivatives: Clentiazem
Diltiazem
Iprotiazem
Nictiazem
Siratiazem; Phenylalkylamines: Anipamil
Dagapamil
Devapamil
Dexverapamil
Emopamil
Etripamil
Falipamil
Gallopamil
Levemopamil
Nexopamil
Norverapamil
Ronipamil
Tiapamil
Verapamil; Others: AH-1058
Brinazarone
Budiodarone
Celivarone
Cyproheptadine
Dronedarone
Fantofarone
SR-33805
Tetrahydropalmatine
N-type-selective: ω-Conotoxins
ω-Conotoxin GVIA
Caroverine
Huwentoxin XVI
Leconotide (ω-conotoxin CVID)
PD-173212
Ralfinamide
Safinamide
Z160
Ziconotide (ω-conotoxin MVIIA)
P-type-selective: ω-Agatoxin IVA
ω-Agatoxin IVB
R-type-selective: SNX-482
T-type-selective: ABT-639
ML-218
Niflumic acid
NNC 55-0396
ProTx I
Z944
Zonisamide
Non-selective: ω-Agatoxin TK
ω-Conotoxin MVIIC
Benidipine
Bepridil
Cilnidipine
Cinnarizine
Dotarizine
Efonidipine
Flunarizine
Lamotrigine
Levetiracetam
Lomerizine
Loperamide
Mibefradil
NP078585
Ruthenium red
TROX-1
α2δ subunit-selective (gabapentinoids): 4-Methylpregabalin
Arbaclofen
Arbaclofen placarbil
Atagabalin
Baclofen
Gabapentin
Gabapentin enacarbil
Imagabalin
Mirogabalin
PD-200,347
PD-217,014
PD-299,685
Phenibut
Pregabalin
Others/unsorted: Bencyclane
Berbamine
Bevantolol
Canadine
Carboxyamidotriazole
Cycleanine
Dauricine
Dimeditiapramine
Diproteverine
Enpiperate
Eperisone
Elpetrigine
Ethadione
Ethanol (alcohol)
Ethosuximide
Fasudil
Fendiline
Fostedil
Imepitoin
JTV-519
Lidoflazine
Magnesium
Manoalide
Mesuximide
Monatepil
Naftopidil
Ochratoxin A
Osthol
Otilonium bromide
Paramethadione
Phensuximide
Pinaverium bromide
Prenylamine
Rhynchophylline
Sesamodil
Silperisone
Sipatrigine
Terodiline
Tetrandrine
Tolperisone
Trimethadione
Valperinol
Activators
L-type-selective: Bay K8644
PotassiumVGKCsBlockers
3,4-Diaminopyridine (amifampridine)
4-Aminopyridine (fampridine/dalfampridine)
Adekalant
Almokalant
Amiodarone
Azimilide
Bretylium
Bunaftine
Charybdotoxin
Clamikalant
Conotoxins
Dalazatide
Dendrotoxin
Dofetilide
Dronedarone
E-4031
Hanatoxin
HgeTx1
HsTx1
Ibutilide
Inakalant
Kaliotoxin
Linopirdine
Lolitrem B
Maurotoxin
Nifekalant
Notoxin
Paxilline
Pinokalant
Quinidine
ShK-186
Sotalol
Tedisamil
Terikalant
Tetraethylammonium
Vernakalant
hERG (KCNH2, Kv11.1)-specific: Ajmaline
Amiodarone
AmmTX3
Astemizole
Azaspiracid
AZD1305
Azimilide
Bedaquiline
BeKm-1
BmTx3
BRL-32872
Chlorpromazine
Cisapride
Clarithromycin
Darifenacin
Dextropropoxyphene
Diallyl trisulfide
Domperidone
E-4031
Ergtoxins
Erythromycin
Gigactonine
Haloperidol
Ketoconazole
Norpropoxyphene
Orphenadrine
Pimozide
PNU-282,987
Promethazine
Quinidine
Ranolazine
Roxithromycin
Sertindole
Solifenacin
Tamulotoxin
Terodiline
Terfenadine
Thioridazine
Tolterodine
Vanoxerine
Vernakalant
KCNQ (Kv7)-specific: Linopirdine
XE-991
Spooky toxin (SsTx)
Activators
KCNQ (Kv7)-specific: Flupirtine
Retigabine
IRKsBlockers
KATP-specific: Acetohexamide
Carbutamide
Chlorpropamide
Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide
Glycyclamide
Metahexamide
Mitiglinide
Nateglinide
Repaglinide
Tolazamide
Tolbutamide
GIRK-specific: Barium
Caramiphen
Cloperastine
Clozapine
Dextromethorphan
Ethosuximide
Ifenprodil
Tertiapin
Tipepidine
Activators
KATP-specific: Aprikalim
Bimakalim
Cromakalim
Diazoxide
Emakalim
Levcromakalim
Mazokalim
Minoxidil
Naminidil
Nicorandil
Pinacidil
Rilmakalim
Sarakalim
GIRK-specific: ML-297 (VU0456810)
KCaBlockers
BKCa-specific: Ethanol (alcohol)
GAL-021
Activators
BKCa-specific: Flufenamic acid
Meclofenamic acid
Niflumic acid
Nimesulide
Rottlerin (mallotoxin)
Tolfenamic acid
K2PsBlockers
12-O-Tetradecanoylphorbol-13-acetate
Arachidonic acid
Fluoxetine
Norfluoxetine
Activators
Riluzole
SodiumVGSCsBlockers
Antianginals: Ranolazine
Antiarrhythmics (class I): Ajmaline
Aprindine
Disopyramide
Dronedarone
Encainide
Flecainide
Lidocaine
Lorajmine
Lorcainide
Mexiletine
Moricizine
Pilsicainide
Prajmaline
Procainamide
Propafenone
Quinidine
Sparteine
Tocainide
Anticonvulsants: Acetylpheneturide
Carbamazepine
Cenobamate
Chlorphenacemide
Elpetrigine
Eslicarbazepine acetate
Ethotoin
Fosphenytoin
Lacosamide
Licarbazepine
Mephenytoin
Oxcarbazepine
Oxitriptyline
Phenacemide
Pheneturide
Phenytoin
Rufinamide
Sipatrigine
Topiramate
Sodium valproate
Valnoctamide
Valproate pivoxil
Valproate semisodium
Valproic acid
Valpromide
Zonisamide
Local anesthetics: pFBT
Amylocaine
Articaine
Benzocaine
Bupivacaine (Levobupivacaine, Ropivacaine)
Butacaine
Butamben
Chloroprocaine
Cinchocaine
Cocaine
Cyclomethycaine
Dimethocaine
Diphenhydramine
Etidocaine
Hexylcaine
Iontocaine
Lidocaine
Mepivacaine
Meprylcaine
Metabutoxycaine
Orthocaine
Piperocaine
Prilocaine
Procaine
Propoxycaine
Proxymetacaine
Risocaine
Tetracaine
Trimecaine
Analgesics: AZD-3161
DSP-2230
Funapide
GDC-0276
NKTR-171
PF-04531083
PF-05089771
Ralfinamide
Raxatrigine
RG7893 (GDC-0287)
Toxins: Conotoxins
Neosaxitoxin
Saxitoxin
Tetrodotoxin
Zetekitoxin AB
Others: Buprenorphine
Evenamide
Menthol (mint)
Safinamide
Tricyclic antidepressants
Activators
Aconitine
Atracotoxins (ω-Atracotoxin, Robustoxin, Versutoxin)
Batrachotoxin
Ciguatoxins
Grayanotoxins
Poneratoxin
ENaCBlockers
Amiloride
Benzamil
Triamterene
Activators
Solnatide
ASICsBlockers
A-317567
Amiloride
Aspirin
Ibuprofen
PcTX1
ChlorideCaCCsBlockers
Crofelemer
DIDS
Ethacrynic acid
Flufenamic acid
Fluoxetine
Furosemide
Glibenclamide
Mefloquine
Mibefradil
Niflumic acid
Activators
Carbachol
CFTRBlockers
Glibenclamide
Lonidamine
Piretanide
Activators
1,7-Phenanthroline
1,10-Phenanthroline
4,7-Phenanthroline
7,8-Benzoquinoline
Ivacaftor
Phenanthridine
UnsortedBlockers
Bumetanide
Flufenamic acid
Meclofenamic acid
Mefenamic acid
Mepacrine
Niflumic acid
Talniflumate
Tolfenamic acid
Trifluoperazine
OthersTRPs
See here instead.
LGICs
See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





